Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the

OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Efficacy in Metastatic Melanoma

First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743 - Annals of Oncology

Figure 3 from Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial - The Lancet Oncology

Double Trouble: Immunotherapy Doublets in Melanoma—Approved and Novel Combinations to Optimize Treatment in Advanced Melanoma

Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study - The Lancet Oncology

Nivolumab-ipilimumab combination demonstrates antitumor activity in prostate cancer subset

Rationale for combining ipilimumab and nivolumab. CTLA-4: Cytotoxic

1694-Melanoma metastatic ipilimumab and nivolumab (induction)

VisualAbstract: Nivolumab plus ipilimumab may be less effective in females with melanoma compared to males

Frontiers Nivolumab plus ipilimumab in metastatic melanoma: a critical appraisal focused on specific subpopulations

The New England Journal of Medicine - In patients with untreated metastatic melanoma, the addition of ipilimumab (anti-CTLA4) to nivolumab (anti-PD1) did not further improve response rate or progression-free survival in PD-L1

Looking into a Better Future: Novel Therapies for Metastatic Melanoma

PDF) Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

Ipilimumab (Yervoy) Drug Information